Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer

European Journal of Nuclear Medicine - Tập 45 - Trang 2285-2299 - 2018
S. R. Dubash1, S. Merchant1, K. Heinzmann1, F. Mauri2, I. Lavdas1, M. Inglese1,3, K. Kozlowski1, N. Rama1, N. Masrour1, J. F. Steel1, A. Thornton1, A. K. Lim2, C. Lewanski4, S. Cleator4, R. C. Coombes4, Laura Kenny1,4, Eric O. Aboagye1
1Department of Surgery and Cancer, Imperial College London Hammersmith Hospital, London, UK
2Department of Radiology, Imperial College Healthcare NHS Trust, London, UK
3Department of Computer, Control and Management Engineering Antonio Ruberti, University of Rome, La Sapienza, Italy
4Department of Oncology, Imperial College Healthcare NHS Trust, London, UK

Tóm tắt

Effective anticancer therapy is thought to involve induction of tumour cell death through apoptosis and/or necrosis. [18F]ICMT-11, an isatin sulfonamide caspase-3/7-specific radiotracer, has been developed for PET imaging and shown to have favourable dosimetry, safety, and biodistribution. We report the translation of [18F]ICMT-11 PET to measure chemotherapy-induced caspase-3/7 activation in breast and lung cancer patients receiving first-line therapy. Breast tumour SUVmax of [18F]ICMT-11 was low at baseline and unchanged following therapy. Measurement of M30/M60 cytokeratin-18 cleavage products showed that therapy was predominantly not apoptosis in nature. While increases in caspase-3 staining on breast histology were seen, post-treatment caspase-3 positivity values were only approximately 1%; this low level of caspase-3 could have limited sensitive detection by [18F]ICMT-11-PET. Fourteen out of 15 breast cancer patients responded to first–line chemotherapy (complete or partial response); one patient had stable disease. Four patients showed increases in regions of high tumour [18F]ICMT-11 intensity on voxel-wise analysis of tumour data (classed as PADS); response was not exclusive to patients with this phenotype. In patients with lung cancer, multi-parametric [18F]ICMT-11 PET and MRI (diffusion-weighted- and dynamic contrast enhanced-MRI) showed that PET changes were concordant with cell death in the absence of significant perfusion changes. This study highlights the potential use of [18F]ICMT-11 PET as a promising candidate for non-invasive imaging of caspase3/7 activation, and the difficulties encountered in assessing early-treatment responses. We summarize that tumour response could occur in the absence of predominant chemotherapy-induced caspase-3/7 activation measured non-invasively across entire tumour lesions in patients with breast and lung cancer.

Tài liệu tham khảo

Ichim G, Tait SW. A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer. 2016;16(8):539–48. https://doi.org/10.1038/nrc.2016.58.

Lopez J, Tait SW. Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer. 2015;112(6):957–62. https://doi.org/10.1038/bjc.2015.85.

Wang F, Fang W, Zhang MR, Zhao M, Liu B, Wang Z, et al. Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labeled C2A domain of synaptotagmin I. J Nucl Med. 2011;52(4):592–9. https://doi.org/10.2967/jnumed.110.081588.

Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A. 2009;106(38):16375–80. https://doi.org/10.1073/pnas.0901310106.

Hoglund J, Shirvan A, Antoni G, Gustavsson SA, Langstrom B, Ringheim A, et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med. 2011;52(5):720–5. https://doi.org/10.2967/jnumed.110.081786.

Bao X, Yang Z, Wang S, Zheng Y, Wang M, Gu B, et al. The preclinical study of predicting radiosensitivity in human nasopharyngeal carcinoma xenografts by 18F-ML-10 animal- PET/CT imaging. Oncotarget. 2016;7(15):20743–52. https://doi.org/10.18632/oncotarget.7868.

Kartachova M, Haas RL, Olmos RA, Hoebers FJ, van Zandwijk N, Verheij M. In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol. 2004;72(3):333–9. https://doi.org/10.1016/j.radonc.2004.07.008.

Hoebers FJ, Kartachova M, de Bois J, van den Brekel MW, van Tinteren H, van Herk M, et al. 99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2008;35(3):509–18. https://doi.org/10.1007/s00259-007-0624-x.

Witney TH, Hoehne A, Reeves RE, Ilovich O, Namavari M, Shen B, et al. A systematic comparison of 18F-C-SNAT to established radiotracer imaging agents for the detection of tumor response to treatment. Clin Cancer Res. 2015;21(17):3896–905. https://doi.org/10.1158/1078-0432.CCR-14-3176.

Reshef A, Shirvan A, Waterhouse RN, Grimberg H, Levin G, Cohen A, et al. Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET. J Nucl Med. 2008;49(9):1520–8. https://doi.org/10.2967/jnumed.107.043919.

Oborski MJ, Laymon CM, Lieberman FS, Drappatz J, Hamilton RL, Mountz JM. First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy. Brain Behav. 2014;4(2):312–5. https://doi.org/10.1002/brb3.217.

Kartachova M, van Zandwijk N, Burgers S, van Tinteren H, Verheij M, Valdes Olmos RA. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol. 2007;25(18):2534–9. https://doi.org/10.1200/JCO.2006.10.1337.

Kazmierczak PM, Burian E, Eschbach R, Hirner-Eppeneder H, Moser M, Havla L, et al. Monitoring cell death in regorafenib-treated experimental colon carcinomas using annexin-based optical fluorescence imaging validated by perfusion MRI. PLoS One. 2015;10(9):e0138452. https://doi.org/10.1371/journal.pone.0138452.

Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer. 2003;89(6):1035–41. https://doi.org/10.1038/sj.bjc.6601173.

Smith G, Glaser M, Perumal M, Nguyen QD, Shan B, Arstad E, et al. Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem. 2008;51(24):8057–67. https://doi.org/10.1021/jm801107u.

Fortt R, Smith G, Awais RO, Luthra SK, Aboagye EO. Automated GMP synthesis of [(18)F]ICMT-11 for in vivo imaging of caspase-3 activity. Nucl Med Biol. 2012;39(7):1000–5. https://doi.org/10.1016/j.nucmedbio.2012.03.004.

Nguyen QD, Lavdas I, Gubbins J, Smith G, Fortt R, Carroll LS, et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res. 2013;19(14):3914–24. https://doi.org/10.1158/1078-0432.CCR-12-3814.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92. https://doi.org/10.1056/NEJMoa1113205.

Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–4. https://doi.org/10.1038/nature09807.

Papaevangelou E, Almeida GS, Jamin Y, Robinson SP, deSouza NM. Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy. Br J Cancer. 2015;112(9):1471–9. https://doi.org/10.1038/bjc.2015.134.

Schmitz JE, Kettunen MI, Hu DE, Brindle KM. 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn Reson Med. 2005;54(1):43–50. https://doi.org/10.1002/mrm.20529.

Banihashemi B, Vlad R, Debeljevic B, Giles A, Kolios MC, Czarnota GJ. Ultrasound imaging of apoptosis in tumor response: novel preclinical monitoring of photodynamic therapy effects. Cancer Res. 2008;68(20):8590–6. https://doi.org/10.1158/0008-5472.CAN-08-0006.

Levin G, Shirvan A, Grimberg H, Reshef A, Yogev-Falach M, Cohen A, et al. Novel fluorescence molecular imaging of chemotherapy-induced intestinal apoptosis. J Biomed Opt. 2009;14(5):054019. https://doi.org/10.1117/1.3253303.

Belhocine TZ, Blankenberg FG, Kartachova MS, Stitt LW, Vanderheyden JL, Hoebers FJ, et al. (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. Eur J Nucl Med Mol Imaging. 2015;42(13):2083–97. https://doi.org/10.1007/s00259-015-3152-0.

Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res. 2007;13(11):3198–206. https://doi.org/10.1158/1078-0432.CCR-07-0009.

Greystoke A, O'Connor JP, Linton K, Taylor MB, Cummings J, Ward T, et al. Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br J Cancer. 2011;104(4):719–25. https://doi.org/10.1038/sj.bjc.6606082.

Witney TH, Fortt R, Aboagye EO. Preclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomography. PLoS One. 2014;9(3):e91694. https://doi.org/10.1371/journal.pone.0091694.

Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012. Cell Death Differ. 2012;19(1):107–20. https://doi.org/10.1038/cdd.2011.96.

Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI—a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol. 2008;5(4):220–33. https://doi.org/10.1038/ncponc1073.

Tourell MC, Shokoohmand A, Landgraf M, Holzapfel NP, Poh PS, Loessner D, et al. The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in ovarian tumour xenografts. Sci Rep. 2017;7:42905. https://doi.org/10.1038/srep42905.

Challapalli A, Kenny LM, Hallett WA, Kozlowski K, Tomasi G, Gudi M, et al. 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med. 2013;54(9):1551–6. https://doi.org/10.2967/jnumed.112.118760.

Morse DL, Galons JP, Payne CM, Jennings DL, Day S, Xia G, et al. MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed. 2007;20(6):602–14. https://doi.org/10.1002/nbm.1127.

Miquel ME, Scott AD, Macdougall ND, Boubertakh R, Bharwani N, Rockall AG. In vitro and in vivo repeatability of abdominal diffusion-weighted MRI. Br J Radiol. 2012;85:1507–12. https://doi.org/10.1259/bjr/32269440.

Yuan J, Chow SK, Yeung DK, Ahuja AT, King AD. Quantitative evaluation of dual-flip-angle T1 mapping on DCE-MRI kinetic parameter estimation in head and neck. Quant Imaging Med Surg. 2012;2(4):245–53. https://doi.org/10.3978/j.issn.2223-4292.2012.11.04.

Dhillon T, Mauri FA, Bellezza G, Cagini L, Barbareschi M, North BV, et al. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol. 2010;5(3):314–9. https://doi.org/10.1097/JTO.0b013e3181ce6604.